Key facts
- It has raised $300K; the latest was Angel (individual) ($150K) in Feb 2025.
- EndoSure has filed 1 Form D with the SEC, most recently Feb 2025 ($150K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for EndoSure
- ·The full record, as it builds
Funding rounds
No funding rounds for EndoSure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EndoSure
Manufacturer of medical device designed to improve early and accurate detection of endometriosis. The company offers a non-invasive test to support the diagnosis of endometriosis that not only fills the gap, but addresses the vacuum in this area of women's health care, enabling customers to achieve a fast and streamlined diagnosis for endometriosis.
- Sector
- Healthcare
- HQ
- Sparks Glencoe, MD, United States
- Founded
- 2022
- Employees
- 8
- Website
- endosure.com/
- Ownership
- Privately Held (backing)
EndoSure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoSure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoSure in its N-PORT filings yet. We sweep new filings monthly.